| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
|
Clin Cancer Res
|
2010
|
2.87
|
|
2
|
Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality.
|
BJU Int
|
2008
|
2.60
|
|
3
|
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.
|
Eur Urol
|
2010
|
2.47
|
|
4
|
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy.
|
Proc Natl Acad Sci U S A
|
2009
|
2.33
|
|
5
|
Expression and prognostic relevance of annexin A3 in prostate cancer.
|
Eur Urol
|
2008
|
2.32
|
|
6
|
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity.
|
BMC Med Genomics
|
2011
|
2.24
|
|
7
|
Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
|
Urology
|
2007
|
1.69
|
|
8
|
Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
|
Prostate
|
2005
|
1.68
|
|
9
|
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
|
J Urol
|
2008
|
1.68
|
|
10
|
Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.
|
J Steroid Biochem Mol Biol
|
2005
|
1.67
|
|
11
|
Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients.
|
Am J Hum Genet
|
2010
|
1.67
|
|
12
|
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.
|
Cancer Res
|
2005
|
1.62
|
|
13
|
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
|
Am J Pathol
|
2012
|
1.48
|
|
14
|
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.
|
Urology
|
2003
|
1.46
|
|
15
|
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.
|
J Urol
|
2004
|
1.44
|
|
16
|
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
|
World J Urol
|
2011
|
1.42
|
|
17
|
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
|
J Urol
|
2003
|
1.40
|
|
18
|
hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.
|
Cancer Res
|
2006
|
1.33
|
|
19
|
The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
|
J Exp Ther Oncol
|
2004
|
1.32
|
|
20
|
Plexin-B1 mutations in prostate cancer.
|
Proc Natl Acad Sci U S A
|
2007
|
1.28
|
|
21
|
The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer.
|
J Mol Med (Berl)
|
2012
|
1.23
|
|
22
|
Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.
|
Am J Epidemiol
|
2006
|
1.21
|
|
23
|
Targeting the insulin-like growth factor network in cancer therapy.
|
Cancer Biol Ther
|
2011
|
1.21
|
|
24
|
Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours.
|
J Steroid Biochem Mol Biol
|
2006
|
1.19
|
|
25
|
Modulated expression of WFDC1 during carcinogenesis and cellular senescence.
|
Carcinogenesis
|
2008
|
1.13
|
|
26
|
Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis.
|
Prostate
|
2005
|
1.12
|
|
27
|
The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection.
|
Prostate
|
2010
|
1.10
|
|
28
|
Genetic alterations in the PI3K pathway in prostate cancer.
|
Anticancer Res
|
2009
|
1.09
|
|
29
|
Androgen receptors in prostate cancer.
|
J Urol
|
2003
|
1.07
|
|
30
|
The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor.
|
Mol Cell Biol
|
2003
|
1.07
|
|
31
|
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
|
Prostate
|
2004
|
1.06
|
|
32
|
Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway.
|
Carcinogenesis
|
2012
|
1.06
|
|
33
|
The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer.
|
J Urol
|
2006
|
1.05
|
|
34
|
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer.
|
Cancer Res
|
2005
|
1.04
|
|
35
|
Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1.
|
Carcinogenesis
|
2009
|
1.03
|
|
36
|
Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer.
|
Mol Cancer
|
2009
|
1.02
|
|
37
|
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21.
|
Am J Pathol
|
2012
|
1.02
|
|
38
|
Molecular effects of the isoflavonoid genistein in prostate cancer.
|
Clin Prostate Cancer
|
2005
|
1.01
|
|
39
|
Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker.
|
J Proteome Res
|
2010
|
1.00
|
|
40
|
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
|
World J Urol
|
2011
|
1.00
|
|
41
|
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.
|
J Steroid Biochem Mol Biol
|
2013
|
0.99
|
|
42
|
Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia.
|
Prostate
|
2003
|
0.99
|
|
43
|
Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility.
|
Endocr Relat Cancer
|
2009
|
0.99
|
|
44
|
Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.
|
Int J Public Health
|
2011
|
0.96
|
|
45
|
Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.96
|
|
46
|
Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
|
Cancer Gene Ther
|
2002
|
0.95
|
|
47
|
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
|
Am J Pathol
|
2003
|
0.95
|
|
48
|
Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
|
World J Urol
|
2012
|
0.94
|
|
49
|
Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells.
|
Endocrinology
|
2012
|
0.94
|
|
50
|
Mitochondrial haplogroups and control region polymorphisms are not associated with prostate cancer in Middle European Caucasians.
|
PLoS One
|
2009
|
0.94
|
|
51
|
Anterior gradient 2 and 3--two prototype androgen-responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells.
|
FEBS J
|
2013
|
0.94
|
|
52
|
A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry.
|
Bioinformatics
|
2008
|
0.93
|
|
53
|
Estrogen promotes prostate cancer cell migration via paracrine release of ENO1 from stromal cells.
|
Mol Endocrinol
|
2012
|
0.93
|
|
54
|
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
|
Mod Pathol
|
2012
|
0.93
|
|
55
|
Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta.
|
Eur Urol
|
2004
|
0.93
|
|
56
|
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.
|
Proc Natl Acad Sci U S A
|
2012
|
0.91
|
|
57
|
Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation.
|
Endocrinology
|
2013
|
0.91
|
|
58
|
Accumulation of mutations over the entire mitochondrial genome of breast cancer cells obtained by tissue microdissection.
|
Breast Cancer Res Treat
|
2010
|
0.91
|
|
59
|
Quantitative measurement of the androgen receptor in prepuces of boys with and without hypospadias.
|
BJU Int
|
2013
|
0.90
|
|
60
|
Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population.
|
Prostate
|
2004
|
0.90
|
|
61
|
Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3.
|
Proteomics
|
2007
|
0.89
|
|
62
|
In vitro model systems to study androgen receptor signaling in prostate cancer.
|
Endocr Relat Cancer
|
2013
|
0.89
|
|
63
|
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.
|
Endocr Relat Cancer
|
2014
|
0.89
|
|
64
|
Insulin-like growth factor binding protein-3 (IGFBP-3) in the prostate and in prostate cancer: local production, distribution and secretion pattern indicate a role in stromal-epithelial interaction.
|
Prostate
|
2008
|
0.89
|
|
65
|
Serum-autoantibodies for discovery of prostate cancer specific biomarkers.
|
Prostate
|
2011
|
0.88
|
|
66
|
Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis.
|
BMC Cancer
|
2013
|
0.88
|
|
67
|
Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy.
|
Int J Cancer
|
2010
|
0.88
|
|
68
|
Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.
|
PLoS One
|
2013
|
0.88
|
|
69
|
Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis.
|
Oncotarget
|
2014
|
0.88
|
|
70
|
Screening for prostate cancer: updated experience from the Tyrol study.
|
Can J Urol
|
2005
|
0.88
|
|
71
|
Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment.
|
Am J Pathol
|
2011
|
0.87
|
|
72
|
Identification of genes involved in estrogenic action in the human prostate using microarray analysis.
|
Genomics
|
2004
|
0.86
|
|
73
|
Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats.
|
Asian J Androl
|
2009
|
0.86
|
|
74
|
Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target?
|
Prostate
|
2013
|
0.85
|
|
75
|
Epithelial-to-mesenchymal transition and estrogen receptor α mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia.
|
Prostate
|
2014
|
0.85
|
|
76
|
Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis.
|
Urol Oncol
|
2008
|
0.85
|
|
77
|
Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue.
|
Eur Urol
|
2002
|
0.85
|
|
78
|
Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2.
|
J Endocrinol
|
2007
|
0.84
|
|
79
|
Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis.
|
Prostate
|
2004
|
0.84
|
|
80
|
Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
|
Int J Cancer
|
2010
|
0.84
|
|
81
|
Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts.
|
Future Oncol
|
2005
|
0.84
|
|
82
|
Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells.
|
Urology
|
2011
|
0.83
|
|
83
|
Human kallikrein 7 induces epithelial-mesenchymal transition-like changes in prostate carcinoma cells: a role in prostate cancer invasion and progression.
|
Anticancer Res
|
2010
|
0.82
|
|
84
|
Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens.
|
Prostate
|
2002
|
0.81
|
|
85
|
MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer.
|
J Proteomics
|
2013
|
0.81
|
|
86
|
Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/mL.
|
Urology
|
2003
|
0.81
|
|
87
|
Insulin-like growth factor-binding protein-5 enters vesicular structures but not the nucleus.
|
Traffic
|
2007
|
0.81
|
|
88
|
Adverse pathological findings in needle biopsy gleason score 6 prostate cancers with low and intermediate preoperative PSA levels following radical prostatectomy.
|
Anticancer Res
|
2012
|
0.81
|
|
89
|
Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.
|
Mol Carcinog
|
2003
|
0.81
|
|
90
|
A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
|
Mol Cancer
|
2014
|
0.80
|
|
91
|
Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055.
|
Phytomedicine
|
2013
|
0.79
|
|
92
|
Estrogens and aspects of prostate disease.
|
Int J Urol
|
2007
|
0.79
|
|
93
|
Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients.
|
J Transl Med
|
2011
|
0.79
|
|
94
|
Gene therapy strategies in prostate cancer.
|
Curr Gene Ther
|
2005
|
0.79
|
|
95
|
Influence of blood sampling on protein profiling and pattern analysis using matrix-assisted laser desorption/ionisation mass spectrometry.
|
BJU Int
|
2007
|
0.79
|
|
96
|
Phytoestrogens derived from Belamcanda chinensis have an antiproliferative effect on prostate cancer cells in vitro.
|
J Urol
|
2004
|
0.79
|
|
97
|
Characterization of normal and malignant prostate tissue by Fourier transform infrared microspectroscopy.
|
Mol Biosyst
|
2010
|
0.78
|
|
98
|
Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells.
|
Mol Endocrinol
|
2010
|
0.78
|
|
99
|
Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer.
|
Clin Prostate Cancer
|
2004
|
0.78
|
|
100
|
Material-enhanced laser desorption/ionization (MELDI)--a new protein profiling tool utilizing specific carrier materials for time of flight mass spectrometric analysis.
|
J Am Soc Mass Spectrom
|
2006
|
0.78
|
|
101
|
Studies on androgen receptor mutations and amplification in human prostate cancer.
|
Methods Mol Med
|
2003
|
0.78
|
|
102
|
Derivatized cellulose combined with MALDI-TOF MS: a new tool for serum protein profiling.
|
J Proteome Res
|
2005
|
0.77
|
|
103
|
Is real-time PCR the correct method to evaluate the incidence of human papillomavirus in prepuces of asymptomatic boys and men?
|
World J Urol
|
2013
|
0.77
|
|
104
|
Prostaglandin E2 induces stromal cell-derived factor-1 expression in prostate stromal cells by activating protein kinase A and transcription factor Sp1.
|
Int J Biochem Cell Biol
|
2012
|
0.76
|
|
105
|
Development of a cell-isolation method for human prostatic smooth muscle cells based on cell type-specific activation of the SM22 gene promoter.
|
BJU Int
|
2006
|
0.75
|
|
106
|
Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo.
|
Int J Mol Sci
|
2013
|
0.75
|
|
107
|
Ability of PSA-positive circulating macrophages to detect prostate cancer.
|
Prostate
|
2005
|
0.75
|
|
108
|
Clinically insignificant improvement of prostate cancer prediction by addition of sex steroid hormones and SHBG serum levels to serum PSA, fPSA%, and age in a screening setting.
|
Horm Mol Biol Clin Investig
|
2012
|
0.75
|
|
109
|
Screening for prostate cancer: updated experience from the Tyrol study.
|
Curr Urol Rep
|
2004
|
0.75
|
|
110
|
Patient-reported urinary incontinence and erectile dysfunction following radical prostatectomy: results from the European Prostate Centre Innsbruck.
|
Urol Int
|
2015
|
0.75
|
|
111
|
Curbing tobacco's toll starts with the professionals: World No Tobacco Day.
|
Lancet
|
2005
|
0.75
|
|
112
|
PGE2 modulates the transcriptional activity of ERRa in prostate stromal cells.
|
Endocrine
|
2014
|
0.75
|